My question was on , in the cardiovascular segment, one cholesterol -lowering drug therapy is doing very well in the global market, right? So, what factor does Neuland consider to gain more market share in the supply chain?
So, growth guidance for which you are giving for F Y26 and beyond, is due to the visibility in this cardiovascular API or any other molecule which drives the growth? Only this.